CRISPR Therapeutics AG
NASDAQ · us_market
No AI insight generated yet for this ticker.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| ARKK | disruptive | 11.31M | $538.19M | 4.19% | Added+7.5% | 2026-03-31 |
| StateStreet | passive | 3.98M | $189.45M | 0.01% | Added+6.1% | 2026-03-31 |
| FidelityFMR | fundamental | 1.95M | $92.98M | 0.00% | Unchanged | 2026-03-31 |
| TwoSigma | quant | 1.48M | $70.55M | 0.06% | Added+215.1% | 2026-03-31 |
| Wellington | fundamental | 34.9K | $1.66M | 0.00% | Added+2.3% | 2026-03-31 |
| TRowePrice | fundamental | 105.0K | $5.00K | 0.00% | Added+23.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -1.18 | — | — |
| 2026-05-04 | -1.23 | -1.28 | -3.68% |
| 2026-02-12 | -1.23 | -1.37 | -11.68% |
| 2025-11-10 | -1.29 | -1.17 | +9.23% |
| 2025-08-04 | -1.40 | -1.29 | +7.81% |
| 2025-05-06 | -1.28 | -1.58 | -23.75% |
| 2025-02-11 | -1.19 | -0.44 | +62.89% |
| 2024-11-05 | -1.40 | -1.01 | +28.11% |
| 2024-08-05 | -1.43 | -1.49 | -4.44% |
| 2024-05-08 | -1.46 | -1.43 | +2.38% |
| 2024-02-21 | 0.05 | 1.10 | +2212.87% |
| 2023-11-06 | -1.95 | -1.41 | +27.68% |
| 2023-08-07 | -2.10 | -0.98 | +53.37% |
| 2023-05-08 | -1.64 | -0.67 | +59.07% |
| 2023-02-21 | -2.27 | -1.41 | +37.93% |
| 2022-11-01 | -2.24 | -2.24 | -0.09% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CRSP | +8.81% | -3.24% | +7.13% | +54.81% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +5.84% | +1.40% | +10.58% | +42.12% |